Silverfin false false 30/11/2025 01/12/2024 30/11/2025 H G G Lywood 23/07/2020 19 March 2026 no description of principal activity 12764037 2025-11-30 12764037 bus:Director1 2025-11-30 12764037 core:CurrentFinancialInstruments 2025-11-30 12764037 core:CurrentFinancialInstruments 2024-11-30 12764037 2024-11-30 12764037 core:ShareCapital 2025-11-30 12764037 core:ShareCapital 2024-11-30 12764037 core:RetainedEarningsAccumulatedLosses 2025-11-30 12764037 core:RetainedEarningsAccumulatedLosses 2024-11-30 12764037 core:ImmediateParent core:CurrentFinancialInstruments 2025-11-30 12764037 core:ImmediateParent core:CurrentFinancialInstruments 2024-11-30 12764037 bus:OrdinaryShareClass1 2025-11-30 12764037 2024-12-01 2025-11-30 12764037 bus:FilletedAccounts 2024-12-01 2025-11-30 12764037 bus:SmallEntities 2024-12-01 2025-11-30 12764037 bus:AuditExemptWithAccountantsReport 2024-12-01 2025-11-30 12764037 bus:PrivateLimitedCompanyLtd 2024-12-01 2025-11-30 12764037 bus:Director1 2024-12-01 2025-11-30 12764037 2023-12-01 2024-11-30 12764037 bus:OrdinaryShareClass1 2024-12-01 2025-11-30 12764037 bus:OrdinaryShareClass1 2023-12-01 2024-11-30 iso4217:GBP xbrli:pure xbrli:shares

Company No: 12764037 (England and Wales)

ELLELE HEALTH LIMITED

Unaudited Financial Statements
For the financial year ended 30 November 2025
Pages for filing with the registrar

ELLELE HEALTH LIMITED

Unaudited Financial Statements

For the financial year ended 30 November 2025

Contents

ELLELE HEALTH LIMITED

STATEMENT OF FINANCIAL POSITION

As at 30 November 2025
ELLELE HEALTH LIMITED

STATEMENT OF FINANCIAL POSITION (continued)

As at 30 November 2025
Note 2025 2024
£ £
Current assets
Debtors 3 118,479 77,280
Cash at bank and in hand 4,050 0
122,529 77,280
Creditors: amounts falling due within one year 4 ( 1,131,533) ( 387,437)
Net current liabilities (1,009,004) (310,157)
Total assets less current liabilities (1,009,004) (310,157)
Net liabilities ( 1,009,004) ( 310,157)
Capital and reserves
Called-up share capital 5 100 100
Profit and loss account ( 1,009,104 ) ( 310,257 )
Total shareholder's deficit ( 1,009,004) ( 310,157)

For the financial year ending 30 November 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The financial statements of Ellele Health Limited (registered number: 12764037) were approved and authorised for issue by the Director. They were signed on its behalf by:

H G G Lywood
Director

19 March 2026

ELLELE HEALTH LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 30 November 2025
ELLELE HEALTH LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 30 November 2025
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

Ellele Health Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the company's registered office is First Floor, 5 Fleet Place, London, EC4M 7RD, United Kingdom.

The financial statements have been prepared under the historical cost convention and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Going concern

At the reporting date the company had net liabilities of £1,009,004. The parent entity has undertaken to provide such financial support as is required to ensure that the company is able to meet its working capital requirements for the foreseeable future. On this basis the director has a reasonable expectation that the company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, he continues to adopt the going concern basis in preparing the financial statements.

Foreign currency

Transactions in foreign currencies are recorded at the rate of exchange at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the Statement of Financial Position date are reported at the rates of exchange prevailing at that date.

Exchange differences are recognised in the Statement of Income and Retained Earnings in the period in which they arise except for exchange differences arising on gains or losses on non-monetary items which are recognised in the Statement of Comprehensive Income.

Employee benefits

Short term benefits
The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Statement of Financial Position date.

Research and Development expenditure

Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated.

Impairment of assets

Assets, other than those measured at fair value, are assessed for indicators of impairment at each Statement of Financial Position date. If there is objective evidence of impairment, an impairment loss is recognised in the Statement of Income and Retained Earnings as described below.

Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.

Financial instruments

The Company only enters into basic financial instruments and transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to and from related parties and investments in non-puttable ordinary shares.

Financial assets
Basic financial assets, including trade and other debtors, and amounts due from related companies, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Financial assets are derecognised when (a) the contractual rights to the cash flows from the asset expire or are settled, or (b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or (c) control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.

Financial liabilities
Basic financial liabilities, including trade and other creditors and accruals, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Financial liabilities are derecognised when the liability is extinguished, that is when the contractual obligation is discharged, cancelled or expires.

Equity instruments
Equity instruments issued by the company are recorded at the fair value of cash or other resources received or receivable, net of direct issue costs. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

2. Employees

2025 2024
Number Number
Monthly average number of persons employed by the company during the year, including the director 3 1

3. Debtors

2025 2024
£ £
Corporation tax 90,000 59,000
Other debtors 28,479 18,280
118,479 77,280

4. Creditors: amounts falling due within one year

2025 2024
£ £
Trade creditors 68,059 27,487
Amounts owed to parent undertakings 1,009,148 315,322
Other taxation and social security 28,821 7,738
Other creditors 25,505 36,890
1,131,533 387,437

5. Called-up share capital

2025 2024
£ £
Allotted, called-up and fully-paid
100,000 Ordinary shares of £ 0.001 each 100 100